Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155176 | 0.91 | PANK3 (0.44) | PANK3DRD2DRD4MMP7ALDH1A1 | |
| SCHEMBL14252793 | 0.77 | DRD2 (0.49) | PANK3CTSSDRD2DRD4MMP7 | |
| SCHEMBL4813294 | 0.77 | DRD2 (0.42) | PANK3CTSSDRD2DRD4MMP7 | |
| SCHEMBL16495543 | 0.76 | PANK3 (0.40) | PANK3DRD2DRD4MMP7ALDH1A1 | |
| SCHEMBL4610993 | 0.76 | LMNA (0.49) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4673423 | 0.75 | RORC (0.42) | PANK3DRD2DRD4MMP7HDAC8 | |
| SCHEMBL4673431 | 0.75 | RORC (0.42) | PANK3DRD2DRD4MMP7HDAC8 | |
| SCHEMBL6787976 | 0.74 | RET (0.40) | PANK3HDAC8KMT2AGPR119 | |
| SCHEMBL6787183 | 0.74 | RET (0.40) | PANK3HDAC8KMT2AGPR119 | |
| SCHEMBL4671294 | 0.74 | MMP1 (0.41) | PANK3DRD2DRD4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | claimed |
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| EP-1261595-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001062751-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | PANK3 4042/4885CTSS 163/4885DRD2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.